Search clinical trials for: Toripalimab

Total 375 results

Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Yongchang Zhang

Completed

Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Xiangya Hospital of Central South University

Recruiting

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

Advanced Biliary Tract Tumors

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 Treatment

China
Sun Yat-sen University

Active, not recruiting

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Nasopharyngeal Carcinoma

China
TJ Biopharma Co., Ltd.

Active, not recruiting

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Advanced Solid Tumor

China
Sun Yat-sen University

Recruiting

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Solid Tumor | Intestinal Flora | Immune Checkpoint Inhibitor

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
Sun Yat-sen University

Recruiting

Toripalimab Combined With CAV/IE Regimen

Soft Tissue Sarcoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Zhujiang Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Urinary Bladder Cancer

China
Peking University Cancer Hospital & Institute

Enrolling by invitation

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Locally Advanced NSCLC

China
Sun Yat-sen University

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Fudan University

Recruiting

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E2)

Early Low Rectal Cancer

China
Shanghai Jiao Tong University School of Medicine

Completed

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Oral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive Therapy

China
Wuhan Union Hospital, China

Not yet recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (PC-1)

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy

China
Peking University Third Hospital

Unknown

Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer. (CCRT+PD-1)

Cervical Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
Shanghai Zhongshan Hospital

Recruiting

Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma (Toripalimab)

Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

Mucosal Melanoma

China
Sun Yat-sen University

Withdrawn

Phase II of Lenvatinib Plus Toripalimab for Advanced HCC

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The Second Affiliated...

Recruiting

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma

China
Shanghai East Hospital

Recruiting

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Gastric Cancer | HER2-low-expressing Gastric Cancer

China
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
Sichuan University

Unknown

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus (STUHCCPVTT)

Unresectable Hepatocellular Cancer | Portal Vein Tumor Thrombus
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
XIANG YANQUN
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Zhujiang Hospital

Recruiting

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Maintenance Therapy

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
RemeGen Co., Ltd.

Not yet recruiting

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Advanced Hepatocellular Carcinoma | Radiotherapy | Sorafenib | Toripalimab

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Hepatobiliary Neoplasm | Liver Neoplasm | Biliary Tract Neoplasms

China
First Affiliated Hospital of Zhejiang University

Recruiting

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Squamous Cell Carcinoma of Head and Neck

China
AIPING ZHOU

Recruiting

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Gastric Cancer Stage III | Gastric Cancer Stage II

China
Fudan University

Not yet recruiting

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
RenJi Hospital

Not yet recruiting

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Immune Checkpoint Inhibitors | Clear-cell Metastatic Renal Cell Carcinoma | Cytoreductive Nephrectomy
Affiliated Cancer Hospital & Institute of Guangzhou...
Hunan Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Metastatic Nasopharyngeal Carcinoma
Wuhan University

Not yet recruiting

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

Recurrent Small Cell Lung Cancer
Sun Yat-sen University

Recruiting

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Xijing Hospital

Not yet recruiting

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Melanoma

China
Henan Cancer Hospital

Not yet recruiting

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

Recurrent Hepatocellular Cancer

Search clinical trials for: Toripalimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations